CLIAC Seeks Role In FDA's Revision Of Lab Test Waiver Policy
This article was originally published in The Gray Sheet
Executive Summary
The Clinical Laboratory Improvement Advisory Committee (CLIAC) requests that FDA postpone guidance or rulemaking on CLIA waiver applications until it makes recommendations on the issue at a February or March 2001 meeting.